Skip to main content

Table 2 Symptom questionnaires and 6-min walk test

From: Baseline characteristics from a 3-year longitudinal study to phenotype subjects with COPD: the FOOTPRINTS study

 

EwAL

GOLD 1

GOLD 2

GOLD 3

A1ATD

P-value

Per-protocol subjects, n

61

122

127

127

19

 

CAT total score

NA

11.2 (5.7)

14.7 (6.2)

16.6 (7.2)

13.4 (7.4)

 < 0.0001

CAT total score, n (%)

      

 < 10

 ≥ 10

NA

NA

45 (36.9)

76 (62.3)

28 (22.0)

99 (78.0)

26 (20.5)

101 (79.5)

7 (36.8)

12 (63.2)

0.0335*

mMRC dyspnoea score, n (%)

      

 < 2

 ≥ 2

NA

NA

107 (87.7)

14 (11.5)

86 (67.7)

41 (32.3)

50 (39.4)

77 (60.6)

10 (52.6)

9 (47.4)

 < 0.0001*

SGRQ total score, n (%)

NA

25.2 (14.4)

34.7 (15.4)

43.0 (16.5)

37.7 (22.3)

 < 0.0001

 < 25

 ≥ 25

 Missing

NA

NA

58 (47.5)

62 (50.8)

2 (1.6)

38 (29.9)

88 (69.3)

1 (0.8)

20 (15.7)

106 (83.5)

1 (0.8)

5 (26.3)

14 (73.7)

0 (0.0)

 < 0.0001*

SGRQ activity score

NA

35.6 (20.2)

48.9 (20.0)

60.1 (18.3)

54.8 (28.1)

 < 0.0001

SGRQ impacts score

NA

17.0 (13.3)

24.0 (16.4)

32.8 (17.9)

27.2 (21.8)

 < 0.0001

SGRQ symptoms score

NA

33.3 (19.4)

42.8 (19.1)

44.9 (22.5)

40.2 (22.5)

0.0020

Total distance covered in 6 MWT, m

573.1 (100.3)

489.3 (91.7)

458.0 (101.3)

403.8 (121.7)

508.6 (114.4)

 < 0.0001

  1. All data are presented as mean (SD) unless noted otherwise
  2. 6MWT 6-min walk test, A1ATD alpha-1-antitrypsin deficiency, CAT COPD Assessment Test, EwAL ex-smokers without airflow limitation, GOLD GOLD, Global Initiative for Chronic Obstructive Lung Disease, mMRC modified Medical Research Council, NA not assessed, SD standard deviation, SGRQ St. George’s Respiratory Questionnaire
  3. *Cochran–Armitage test for trend. A linear regression test was used for other variables